RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.

PURPOSE To evaluate frequency, biologic features, and clinical relevance of RUNX1 mutations in acute myeloid leukemia (AML). PATIENTS AND METHODS Diagnostic samples from 945 patients (age 18 to 60 years) were analyzed for RUNX1 mutations. In a subset of cases (n = 269), microarray gene expression analysis was performed. RESULTS Fifty-nine RUNX1 mutations were identified in 53 (5.6%) of 945 cases, predominantly in exons 3 (n = 11), 4 (n = 10), and 8 (n = 23). RUNX1 mutations clustered in the intermediate-risk cytogenetic group (46 of 640, 7.2%; cytogenetically normal, 34 of 538, 6.3%), whereas they were less frequent in adverse-risk cytogenetics (five of 109, 4.6%) and absent in core-binding-factor AML (0 of 77) and acute promyelocytic leukemia (0 of 61). RUNX1 mutations were associated with MLL-partial tandem duplications (P = .0007) and IDH1/IDH2 mutations (P = .03), inversely correlated with NPM1 (P < .0001), and in trend with CEBPA (P = .10) mutations. RUNX1 mutations were characterized by a distinct gene expression pattern; this RUNX1 mutation-derived signature was not exclusive for the mutation, but also included mostly adverse-risk AML [eg, 7q-, -7, inv(3), or t(3;3)]. RUNX1 mutations predicted for resistance to chemotherapy (rates of refractory disease 30% and 19%, P = .047, for RUNX1-mutated and wild-type patients, respectively), as well as inferior event-free survival (EFS; P < .0001), relapse-free survival (RFS, P = .022), and overall survival (P = .051). In multivariable analysis, RUNX1 mutations were an independent prognostic marker for shorter EFS (P = .007). Explorative subgroup analysis revealed that allogeneic hematopoietic stem-cell transplantation had a favorable impact on RFS in RUNX1-mutated patients (P < .0001). CONCLUSION AML with RUNX1 mutations are characterized by distinct genetic properties and are associated with resistance to therapy and inferior outcome.

[1]  KyungMann Kim,et al.  Contrasting treatment‐specific survival using double‐robust estimators , 2012 .

[2]  R. Verhaak,et al.  Prognostically useful gene-expression profiles in acute myeloid leukemia. , 2004, The New England journal of medicine.

[3]  P. Opolon,et al.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.

[4]  T. Naoe,et al.  Dual mutations in the AML1 and FLT3 genes are associated with leukemogenesis in acute myeloblastic leukemia of the M0 subtype , 2003, Leukemia.

[5]  M. Caligiuri,et al.  IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  David R. Liu,et al.  Conversion of 5-Methylcytosine to 5- Hydroxymethylcytosine in Mammalian DNA by the MLL Partner TET1 , 2009 .

[7]  T. Haferlach,et al.  Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. , 2007, Blood.

[8]  S. Fröhling,et al.  High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia , 2005, Leukemia.

[9]  D. Gilliland,et al.  Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML , 2009, Leukemia.

[10]  M. Caligiuri,et al.  BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Grambsch,et al.  Modeling Survival Data: Extending the Cox Model , 2000 .

[12]  H. Yamasaki,et al.  Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. , 1999, Blood.

[13]  A. Hagemeijer,et al.  Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.

[14]  G. Seitz,et al.  The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia. , 2001, Haematologica.

[15]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[16]  S. Rollinson,et al.  Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7 , 2002, Genes, chromosomes & cancer.

[17]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.

[18]  D. Birnbaum,et al.  TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). , 2009, Blood.

[19]  J. Soulier,et al.  Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. , 2010, Blood.

[20]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[21]  L. Bullinger,et al.  Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. , 2009, Blood.

[22]  L. Aravind,et al.  Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 , 2010, Nature.

[23]  Fatima Al-Shahrour,et al.  Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia , 2010, Nature Medicine.

[24]  Torsten Haferlach,et al.  Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Robert Tibshirani,et al.  An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. , 2008, Blood.

[26]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[27]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[28]  K. Döhner,et al.  Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics. , 2008, Seminars in oncology.

[29]  John M. Maris,et al.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.

[30]  E. Macintyre,et al.  High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21. , 2000, Blood.

[31]  Joshua F. McMichael,et al.  DNMT3A mutations in acute myeloid leukemia. , 2010, The New England journal of medicine.

[32]  H. Drexler,et al.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.

[33]  R. Tibshirani,et al.  Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. , 2004, The New England journal of medicine.

[34]  Christopher J Schofield,et al.  Expanding chemical biology of 2-oxoglutarate oxygenases. , 2008, Nature chemical biology.

[35]  K. Döhner,et al.  TET genes: new players in DNA demethylation and important determinants for stemness. , 2011, Experimental hematology.

[36]  M. Caligiuri,et al.  TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Yoshiaki Ito.  Oncogenic potential of the RUNX gene family: ‘Overview’ , 2004, Oncogene.

[38]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[39]  K. Wagner,et al.  Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  D. Littman,et al.  Epigenetic gene silencing by Runx proteins , 2004, Oncogene.

[41]  J. Pollack,et al.  KIT mutations confer a distinct gene expression signature in core binding factor leukaemia , 2010, British journal of haematology.

[42]  G. Basso,et al.  Hepatocyte Growth Factor Receptor c-MET Is Associated with FAS and When Activated Enhances Drug-induced Apoptosis in Pediatric B Acute Lymphoblastic Leukemia with TEL-AML1 Translocation* , 2007, Journal of Biological Chemistry.

[43]  E. Korn.  Censoring distributions as a measure of follow-up in survival analysis. , 1986, Statistics in medicine.

[44]  Sunil J Rao,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .

[45]  Michael Heuser,et al.  Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. , 2010, Blood.

[46]  J. Jansen,et al.  TET proteins in malignant hematopoiesis , 2009, Cell cycle.

[47]  E. Thiel,et al.  The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group. , 2009, Blood.

[48]  A. Toker,et al.  NFAT proteins: emerging roles in cancer progression , 2009, Nature Reviews Cancer.

[49]  A. Tefferi,et al.  Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 , 2010, Leukemia.

[50]  L. Bullinger,et al.  Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia. , 2008, Seminars in oncology.

[51]  Jungwon Huh,et al.  Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. , 2009, Blood.

[52]  D. Gilliland,et al.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.

[53]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[54]  D. Gilliland,et al.  TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis , 2009, Leukemia.

[55]  O. Heidenreich,et al.  siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts , 2006, Oncogene.

[56]  Manuela Zucknick,et al.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  B. Leber,et al.  Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy. , 2008, Blood.

[58]  K. Döhner,et al.  Molecular characterization of acute myeloid leukemia , 2008, Haematologica.

[59]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Daniel Birnbaum,et al.  Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias , 2010, BMC Cancer.

[61]  Y. Hayashi,et al.  AML1/RUNX1 mutations are infrequent, but related to AML‐M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies , 2003, Genes, chromosomes & cancer.

[62]  Chieh-Yu Liu,et al.  AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. , 2009, Blood.

[63]  C. Bloomfield,et al.  Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? , 2007, Blood.

[64]  T. Kyo,et al.  High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. , 2004, Blood.

[65]  B. Ko,et al.  Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. , 2010, Blood.

[66]  O. Abdel-Wahab,et al.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.

[67]  J. Rowley,et al.  Leukaemogenesis: more than mutant genes , 2010, Nature Reviews Cancer.

[68]  Axel Benner,et al.  Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.

[69]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[70]  Franz Király,et al.  Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.